Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
$0.17
$0.17
$0.09
$0.22
$29.17M2.47N/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.95
-1.8%
$0.99
$0.81
$3.02
$38.56M2.791.07 million shs491,961 shs
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$0.88
$0.88
$0.62
$1.47
$26.53M1.221,000 shsN/A
Tocagen Inc stock logo
TOCA
Tocagen
$13.66
-1.3%
$32.24
$0.42
$6.77
$326.73M0.011.47 million shs23,706 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
0.00%0.00%0.00%0.00%0.00%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
0.00%-5.84%-0.92%-15.84%-15.09%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00%0.00%0.00%0.00%0.00%
Tocagen Inc stock logo
TOCA
Tocagen
-1.30%+19.72%+43.04%+107.60%+2,507.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1.9069 of 5 stars
3.53.00.00.02.30.00.0
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/AN/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
0.00
N/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
3.00
Buy$9.00846.37% Upside
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00
N/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PXSLY, ITRM, IGXT, and TOCA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$9.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
$1.04M28.05N/AN/A($0.07) per share-2.39
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/A($0.15) per shareN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$8.75M3.03N/AN/A$0.04 per share22.00
Tocagen Inc stock logo
TOCA
Tocagen
$40K8,168.34N/AN/A$0.45 per share30.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
-$9.93M-$0.06N/AN/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$24.77M-$0.99N/AN/AN/AN/A-71.37%8/13/2025 (Estimated)
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
-$9.36MN/A0.00N/AN/AN/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/A

Latest PXSLY, ITRM, IGXT, and TOCA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.14-$0.14N/A-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
N/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
N/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/A
3.72
3.58
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
2.82
3.31
2.92
Tocagen Inc stock logo
TOCA
Tocagen
1.88
1.15
1.15

Institutional Ownership

CompanyInstitutional Ownership
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
N/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.21%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A
Tocagen Inc stock logo
TOCA
Tocagen
21.42%

Insider Ownership

CompanyInsider Ownership
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
42.05%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.20%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A
Tocagen Inc stock logo
TOCA
Tocagen
10.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
38174.66 million101.21 millionNot Optionable
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1040.00 million36.32 millionNot Optionable
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
6930.15 millionN/ANot Optionable
Tocagen Inc stock logo
TOCA
Tocagen
7723.92 millionN/ANot Optionable

Recent News About These Companies

Tocagen plummets on phase 3 data for glioma therapy
Celgene hopes device + drug can tackle aggressive brain tumours
Forte Biosciences Inc (FBRX)
RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying

New MarketBeat Followers Over Time

Media Sentiment Over Time

IntelGenx Technologies stock logo

IntelGenx Technologies OTCMKTS:IGXT

$0.17 0.00 (0.00%)
As of 05/27/2025

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Iterum Therapeutics stock logo

Iterum Therapeutics NASDAQ:ITRM

$0.95 -0.02 (-1.76%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$0.95 0.00 (0.00%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Pharmaxis stock logo

Pharmaxis OTCMKTS:PXSLY

$0.88 0.00 (0.00%)
As of 06/8/2021

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

Tocagen stock logo

Tocagen NASDAQ:TOCA

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.